Default company panoramic image

Genable Technologies Limited

Ophthalmic gene therapy platform

  • Stage Product In Development
  • Industry Biotechnology
  • Location Dublin, Ierland
  • Currency USD
  • Website

Company Summary

Genable is developing new gene medicines to treat "dominant" genetic diseases. Genable utilizes AAV vectors to obtain expression of RNA interference molecules which suppress the expression of faulty gene copies and replaces this with a gene which is refractory to suppression. Genable's first gene medicine - GT038 - is for treatment of patients with rhodopsin (RHO)-linked autosomal dominant retinitis pigmentosa.


  • Default avatar
    Jane Farrar

    Chief Scientific Officer

  • Default avatar
    Alan Boyd

    Head of Regulatory Affairs

  • Default avatar
    Paul Kenna

    Chief Medical Officer